ArticleCancer communications (London, England)2019
CD137 expression in cancer cells: regulation and significance.
Article in Cancer communications (London, England), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 17 citations in OpenAlex.
- Non-classical immune checkpoint CD137/CD137L and CD200/CD200R expressions are regulated by the tumor immune microenvironment in lymph node aspirates from lung cancer patients.Frontiers in immunology · 2026Article
- Exploring potential associations and biomarkers linked polycystic ovarian syndrome with atherosclerosis via comprehensive bioinformatics analysis, machine learning, and animal experiments.Functional & integrative genomics · 2025Article
- Polyclonal expansion of functional tumor-reactive lymphocytes infiltrating glioblastoma for personalized cell therapy.Nature communications · 2025Article
- CD137 in tuberculosis: a scoping review of an emerging immune checkpoint at the crossroads of diagnosis, prognosis, and therapy.Frontiers in immunology · 2025Article
- Exogenous or in situ vaccination to trigger clinical responses in pancreatic cancer.Carcinogenesis · 2024Review
- Cysteine-binding adjuvant enhances survival and promotes immune function in a murine model of acute myeloid leukemia.Blood advances · 2024Article
- Characterizing influence of rCHOP treatment on diffuse large B-cell lymphoma microenvironment through in vitro microfluidic spheroid model.Cell death & disease · 2024Article
- Biomarkers for Immune Checkpoint Inhibitor Response in NSCLC: Current Developments and Applicability.International journal of molecular sciences · 2023Review
- Epigenetic Modification of PD-1/PD-L1-Mediated Cancer Immunotherapy against Melanoma.International journal of molecular sciences · 2022Review
- Novel Paired Cell Lines for the Study of Lipid Metabolism and Cancer Stemness of Hepatocellular Carcinoma.Frontiers in cell and developmental biology · 2022Article
- Immune-and Metabolism-Associated Molecular Classification of Ovarian Cancer.Frontiers in oncology · 2022Article
Corrections and comments
- Comment on
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.